Engineering Nanovaccines for Dendritic Cell-Targeted Immunotherapy
Friday, July 18, 2025
9:16 AM – 9:27 AM EDT
Introduction: Dendritic cells (DCs) initiate and coordinate adaptive immune responses against cancer, but their functions are generally limited by antigen delivery. Engineering nanovaccines capable of targeting dendritic cells (DCs) is desperately required to maximize antigen cross-presentation to effector immune cells, elicit strong immune responses and avoid adverse reactions. Here, we showed that glucose transporter 1 (Glut-1) on DCs is a reliable target for delivering antigens to DCs, and thus a versatile antigen delivery strategy using glucosylated nanovaccines was developed.
Learning Objectives:
At the completion of this activity, participants will know
Confirm glucose transporter 1 (Glut-1) on DCs is a reliable target for delivering antigens to DCs
Glucosylated nanovaccines can target DCs via interacting with Glut-1 for promoted immunotherapy.
